Zoetis Inc. (ETR:ZOE)

Germany flag Germany · Delayed Price · Currency is EUR
127.56
+1.24 (0.98%)
Oct 22, 2025, 5:35 PM CET
0.98%
Market Cap55.76B
Revenue (ttm)7.99B
Net Income (ttm)2.22B
Shares Outn/a
EPS (ttm)4.95
PE Ratio25.07
Forward PE22.32
Dividend1.75 (1.39%)
Ex-Dividend DateJul 18, 2025
Volume441
Average Volume259
Open126.78
Previous Close126.32
Day's Range125.94 - 128.16
52-Week Range119.54 - 176.26
Beta0.90
RSI58.83
Earnings DateNov 4, 2025

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]

Sector Healthcare
Founded 1950
Employees 13,800
Stock Exchange Deutsche Börse Xetra
Ticker Symbol ZOE
Full Company Profile

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Financial numbers in USD Financial Statements

News

Zoetis Stock: Outlook Remains Muted

Zoetis Inc. (NYSE: ZTS) is currently in its final 18th phase of the Adhishthana cycle on the weekly charts. Having formed a poor triad structure, the stock's outlook doesn't look encouraging. With UB...

1 day ago - Benzinga

Zoetis Stock: Outlook Remains Muted

Zoetis Inc. (NYSE:ZTS) is currently in its final 18th phase of the Adhishthana cycle on the weekly charts. Having formed a poor triad structure, the stock's outlook doesn't look encouraging.

1 day ago - Benzinga

Zoetis (ZTS): UBS Maintains Neutral Rating, Lowers Price Target to $158 | ZTS Stock News

Zoetis (ZTS): UBS Maintains Neutral Rating, Lowers Price Target to $158 | ZTS Stock News

1 day ago - GuruFocus

Zoetis (ZTS) Gains Health Canada Approval for Canine Osteoarthritis Pain Relief

Zoetis (ZTS) Gains Health Canada Approval for Canine Osteoarthritis Pain Relief

7 days ago - GuruFocus

Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Lenivia approval by Health Canada marks major milestone in the company's continued innovation for canine OA pain.

7 days ago - Business Wire

Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

8 days ago - Nasdaq

Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain

ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.

9 days ago - Nasdaq

Zoetis (ZTS): EMA Supports New Canine Osteoarthritis Treatment

Zoetis (ZTS): EMA Supports New Canine Osteoarthritis Treatment

11 days ago - GuruFocus

Zoetis (ZTS) Awaits EU Approval for Lenivia, an Osteoarthritis Treatment for Dogs

Zoetis (ZTS) Awaits EU Approval for Lenivia, an Osteoarthritis Treatment for Dogs

11 days ago - GuruFocus

Zoetis Receives Positive Opinion from CVMP for Lenivia (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing aut...

11 days ago - Wallstreet:Online

Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection.

11 days ago - Business Wire

Daily Dividend Report: ZTS,DOW,R,PFE,LMT,NWN

The Board of Directors of Zoetis has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Comp...

12 days ago - Nasdaq

Zoetis Inc. (ZTS) Announces Fourth Quarter Dividend

Zoetis Inc. (ZTS) Announces Fourth Quarter Dividend

12 days ago - GuruFocus

Zoetis (ZTS) Maintains Quarterly Dividend, Sets Payment Date

Zoetis (ZTS) Maintains Quarterly Dividend, Sets Payment Date

12 days ago - GuruFocus

Zoetis Declares Fourth Quarter 2025 Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will ...

12 days ago - Business Wire

VHT, PFE, BMY, ZTS: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an appro...

16 days ago - Nasdaq

Top 50 High-Quality Dividend Growth Stocks For October 2025

I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future ...

19 days ago - Seeking Alpha

Zoetis: A Solid Investment in the Growing Pet Medicine Market?

Could Zoetis be the next big opportunity in the pet medicine market? Tune in as our experts break down the company's strengths and weaknesses.

19 days ago - The Motley Fool

Zoetis: Much Bark, Little Bite - The Stock Remains Pricey

Zoetis Inc. is a global animal health leader with strong fundamentals and a robust innovation pipeline. Click here to read why ZTS stock is a Sell.

20 days ago - Seeking Alpha

Top 15 High-Growth Dividend Stocks For October 2025

The Top 15 High-Growth Dividend Stock list for October 2025 targets a 12% long-term return, despite underperforming SPY and VIG in September. These 15 stocks offer a 1.4% average yield and have grown ...

20 days ago - Seeking Alpha

Zoetis (ZTS) Gains FDA Nod for Innovative Livestock Parasite Treatment

Zoetis (ZTS) Gains FDA Nod for Innovative Livestock Parasite Treatment

21 days ago - GuruFocus

Zoetis granted conditional approval of Dectomax-CA1 for parasitic infection in cattle

FDA conditionally approves Dectomax-CA1 to treat New World screwworm in cattle. Read more here.

21 days ago - Seeking Alpha

Zoetis Receives Conditional Approval for Dectomax-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

Zoetis Inc. today announced that Dectomax-CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for the prevention an...

21 days ago - Wallstreet:Online

Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from ...

21 days ago - Business Wire